The objective was to investigate the impact of a pay-for-performance program (P4P) on quality care and outcomes among cardiovascular disease (CVD) patients. Claims data were used to identify CVD patients in a commercial plan in 1999-2006. Multivariate analyses were employed to examine the impact of P4P on quality care (lipid monitoring and treatment) and quality care on outcomes (new coronary events, hospitalizations, and lipid control). Patients who were treated by physicians participating in P4P were more likely to receive quality care than patients who were not. Patients who received quality care were less likely to have new coronary events (odds ratio [OR] = 0.80; 95% confidence interval [CI] = 0.69-0.92), be hospitalized (OR = 0.76; 95% CI = 0.69-0.83), or have uncontrolled lipids (OR = 0.67; 95% CI = 0.61-0.73) than patients who did not. A P4P program was associated with increased lipid monitoring and treatment. Receipt of this quality care was associated with improved lipid control and reduced likelihood of new coronary events and hospitalizations.
HeronMHoyertDLMurphySLXuJKochanekKDTejada-VeraB. Deaths: final data for 2006. Natl Vital Stat Rep. 2009;57(14):1-134.
2.
PedersenTRKjekshusJBergK. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atheroscler Suppl. 1994;5:81-87.
3.
SacksFMPfefferMAMoyeLA. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-1009.
4.
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349-1357.
5.
SchwartzGGOlssonAGEzekowitzMD. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711-1718.
6.
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
7.
SeverPSDahlofBPoulterNR. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs. 2004;64(suppl 2):43-60.
8.
ShepherdJBlauwGJMurphyMB. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623-1630.
9.
CannonCPBraunwaldEMcCabeCH. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
10.
SmithSCJrAllenJBlairSN. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113:2363-2372.
11.
LeeHYCookeCERobertsonTA. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge. J Manag Care Pharm. 2008;14:271-280.
12.
McGlynnEAAschSMAdamsJ. The quality of health care delivered to adults in the United States. N Engl J Med. 2003;348:2635-2645.
13.
VinkerSShaniMBaevskyTElhayanyA. Adherence with statins over 8 years in a usual care setting. Am J Manag Care. 2008;14:388-392.
14.
SchultzJSO’DonnellJCMcDonoughKLSasaneRMeyerJ. Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population. Am J Manag Care. 2005;11:306-312.
YoungGJMeterkoMBeckmanH. Effects of paying physicians based on their relative performance for quality. J Gen Intern Med. 2007;22:872-876.
17.
SpencerFAAllegroneJGoldbergRJ. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med. 2004;140:857-866.
18.
DudlRJWangMCWongMBellowsJ. Preventing myocardial infarction and stroke with a simplified bundle of cardioprotective medications. Am J Manag Care. 2009;15:e88-e94.
19.
MillettCNetuveliGSaxenaSMajeedA. Impact of pay for performance on ethnic disparities in intermediate outcomes for diabetes: a longitudinal study. Diabetes Care. 2009;32:404-409.
GilmoreASZhaoYKangN. Patient outcomes and evidence-based medicine in a preferred provider organization setting: a six-year evaluation of a physician pay-for-performance program. Health Serv Res. 2007;42(6 pt 1): 2140-2159.
22.
National Committee for Quality Assurance. HEDIS 2008 Technical Specification for Physician Measurement. Washington, DC: National Committee for Quality Assurance; 2007.
23.
ElixhauserASteinerCHarrisDRCoffeyRM. Comorbidity measures for use with administrative data. Med Care. 1998;36:8-27.
24.
Van HerckPDe SmedtDAnnemansLRemmenRRosenthalMBSermeusW. Systematic review: effects, design choices, and context of pay-for-performance in health care. BMC Health Serv Res. 2010;10:247.
25.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
26.
MiettinenTAPyoralaKOlssonAG. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation. 1997;96:4211-4218.
27.
SantosRDWatersDDTarasenkoL. Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: the Lipid Treatment Assessment Project (L-TAP) 2. Am Heart J. 2009;158:860-866.
28.
EnriquezJRPratapPZbilutJPCalvinJEVolgmanAS. Women tolerate drug therapy for coronary artery disease as well as men do, but are treated less frequently with aspirin, beta-blockers, or statins. Gend Med. 2008;5:53-61.
29.
FerdinandKC. Ethnic, gender, and age-related differences in the treatment of dyslipidemia. Am J Manag Care. 2006; 12(15 suppl):S400-S404.
30.
WengerNKLewisSJWeltyFKHerringtonDMBittnerV. Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study. Heart. 2008;94:434-439.
31.
KoDTMamdaniMAlterDA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA. 2004;291:1864-1870.
